

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Darrow et al. Atty Docket: ORT-1552

Serial No.: 10/015,989 Art Unit: 1652

Filed: December 10, 2001 Examiner: W. Moore

For: ZYMOGEN ACTIVATION Confirmation No.: 3814

SYSTEM

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Attention: Doshie E. Day, Office of Initial Patent Examination

RESPONSE TO COMMUNICATION REGARDING RAW SEQUENCE LISTING ERROR REPORT

Sir:

This is a response to the official letter attaching a Raw Sequence Listing Error Report dated August 10, 2004 (copy enclosed). The information requested in the communication is submitted herewith.

It is believed that no fee is due. However, if it is determined that a fee is due in connection with the filing of this response, please charge all required fees to Deposit Account No. 10-0750.

To correct the informalities identified in the Report in accordance with 37 C.F.R. § 1.825, Applicant submits herewith a Substitute Sequence Listing on paper and a

copy on diskette in computer readable form. Pursuant to 37 C.F.R. §1.825, the undersigned states that the copy of the Substitute Sequence Listing in computer readable form is the same as the paper version of the Substitute Sequence Listing. The undersigned further states that the Substitute Sequence Listing introduces no new matter, insofar as it corrects apparent informalities in the Sequence Listing as originally filed.

In view of the foregoing, the requirements of 37 C.F.R. §§ 1.821 - 1.825 have been met. Accordingly, Applicant requests prompt examination on the merits.

Respectfully submitted,

Date: September 9, 2004

Linda S. Evans Reg. No. 33,873

Linda S. Evans Michael D. Ruse Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, New Jersey 08933-7003 (858) 320-3406